HR Execs on the Move

Mixhers

www.mixhers.com

 
Mixhers is a company that provides supplements designed specifically for womens health and wellness, with each product carefully crafted to support women in all stages of life.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Amanda Rasmussen
Director of Supply Chain and Logistics Profile
Britnee Nuehring
Chief Sales Marketing Officer Profile

Similar Companies

BeyondSpring

BeyondSpring is a Global, Clinical-Stage. Bio-pharmaceutical Company. Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.

Hitech Air Conditioning Inc

Hitech Air Conditioning Inc is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Site Management Solutions

Site Management Solutions is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mankind Pharma

Mankind Pharma is one of the Indian leading pharmaceutical companies, and changes the pharma industry by providing world class medications at affordable prices and maintaining quality standards by using state-of-the-art technology for production of hig...

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.